Crossmark

High pretreatment level of soluble interleukin-2 receptor is a robust prognostic factor in patients with follicular lymphoma treated with R-CHOP-like therapy

Crossref DOI link: https://doi.org/10.1038/bcj.2017.96

Published Online: 2017-09-29

Update policy: https://doi.org/10.1007/springer_crossmark_policy

Authors

Kusano, Y

Yokoyama, M

Terui, Y

Inoue, N

Takahashi, A

Yamauchi, H

Tsuyama, N

Nishimura, N

Mishima, Y

Takeuchi, K

Hatake, K
License Information

Text and Data Mining valid from 2017-09-29

Version of Record valid from 2017-09-29
More Information

Article History

First Online: 29 September 2017

Competing interests

: All authors except the following four have no conflict of interest to declare:YT has reported honoraria from Janssen. MY, YM and NN have reported consultancy from Chugai. KH has reported consultancy from Meiji-Seika and Otsuka, honoraria from Kyowa Kirin and research funding from Chugai and Kyowa Kirin.

Document is current

Any future updates will be listed below